Pyrilutamide
| Clinical data | |
|---|---|
| Other names | KX-826; KX826 |
| Routes of administration | Topical[1] |
| Drug class | Nonsteroidal antiandrogen; Androgen receptor antagonist |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C21H15F5N4O2S |
| Molar mass | 482.43 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pyrilutamide (developmental code name KX-826) is a nonsteroidal antiandrogen (NSAA) which is under development for the treatment of androgenic alopecia (pattern hair loss) and acne.[1][2][3] The drug is being developed by Suzhou Kintor Pharmaceuticals.[1] As of February 2025, it is in phase 3 clinical trials for androgenic alopecia and phase 2 trials for acne.[1] The drug was also under development for the treatment of diabetic foot ulcers, but development for this indication was discontinued.[1]
Pharmacology
Pharmacodynamics
Pyrilutamide is a selective and high-affinity silent antagonist of the androgen receptor (AR). It has an affinity (IC50) of 0.28 nM, relative to 3.1 nM in the case of bicalutamide.[3]
See also
- List of investigational acne drugs
- List of investigational hair loss drugs
- GT-20029 (AR-PROTAC)
- Clascoterone (Winlevi; Breezula; CB-03-01)
References
- ^ a b c d e "Pyrilutamide - Suzhou Kintor Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
- ^ Saceda-Corralo D, Domínguez-Santas M, Vañó-Galván S, Grimalt R (January 2023). "What's New in Therapy for Male Androgenetic Alopecia?". American Journal of Clinical Dermatology. 24 (1): 15–24. doi:10.1007/s40257-022-00730-y. PMID 36169916.
- ^ a b CA patent 2829322, Tong Y, "Substituted Thioimidazolidinone Androgen Receptor Antagonists and Uses Thereof", published 2012-03-08, issued 2017-01-10, assigned to Suzhou Kintor Pharmaceuticals, Inc